LOGIN
Volume:7
Issue:8
Number:17
ISSN#:2564-2537
RCT
ACE Report #10576
Dronabinol effective in reducing neuropathic pain in multiple sclerosis after 48-week treatment
How to Cite
OrthoEvidence. Dronabinol effective in reducing neuropathic pain in multiple sclerosis after 48-week treatment. ACE Report. 2018;7(8):17. Available from: https://myorthoevidence.com/AceReport/Report/10576
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Dronabinol is a safe long-term treatment option for neuropathic pain patients
Eur Neurol. 2017;78(5-6):320-329.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
240 patients who had neuropathic pain that was associated with multiple sclerosis (MS) were randomly assigned to receive either dronabinol 7.5-15.0 mg daily for 16 weeks, or its respective placebo with the identical schedule. No significant differences in pain reduction and quality of life improvement were found in patients that received dronabinol compared to those that received placebo. In a fol...
To view the full report, start your 30-day free trial today
No credit card required
JOIN LOGIN Forgot Password?Not sure if you want to join OrthoEvidence?
Access this report without an Account.Success, an email containing a link to access this report has been sent to your inbox.
Explore some of our unlocked reports below!
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MOREFor Reprints and Permissions, click here
Please Login or Join to leave comments.